Working… Menu
Trial record 1 of 1 for:    Fight-302
Previous Study | Return to List | Next Study

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03656536
Recruitment Status : Recruiting
First Posted : September 3, 2018
Last Update Posted : August 9, 2019
Information provided by (Responsible Party):
Incyte Corporation

Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.

Condition or disease Intervention/treatment Phase
Unresectable Cholangiocarcinoma Metastatic Cholangiocarcinoma Drug: Pemigatinib Drug: Gemcitabine Drug: Cisplatin Phase 3

Expanded Access : An investigational treatment associated with this study is no longer available outside the clinical trial.   More info ...

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 432 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)
Actual Study Start Date : December 13, 2018
Estimated Primary Completion Date : March 2022
Estimated Study Completion Date : March 2023

Arm Intervention/treatment
Experimental: Pemigatinib Drug: Pemigatinib
Pemigatinib at the protocol-defined dose administered orally once daily as continuous therapy schedule (a cycle is 3 weeks).
Other Name: INCB054828

Active Comparator: Gemcitabine + Cisplatin
Participants who experience disease progression while receiving gemcitabine + cisplatin or during the follow-up period and before starting a new anticancer therapy will be eligible allowed to cross over and receive pemigatinib.
Drug: Gemcitabine
Gemcitabine 1000 mg/m^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.

Drug: Cisplatin
Cisplatin 25 mg/m^2 administered as an intravenous infusion on Days 1 and 8 of every 3-week cycle for up to 8 cycles.

Primary Outcome Measures :
  1. Progression-free survival [ Time Frame: Up to approximately 12 months ]
    Defined as the time from date of randomization until date of disease progression (according to Response Evaluation Criteria in Solid Tumors [RECIST] v1.1 and assessed by an independent central reviewer (ICR)) or death, whichever occurs first.

Secondary Outcome Measures :
  1. Overall response rate [ Time Frame: Up to approximately 12 months ]
    Defined as the proportion of participants with best overall response of complete response (CR) or partial response (PR) per RECIST v1.1 as assessed by an ICR.

  2. Overall survival [ Time Frame: Up to approximately 12 months ]
    Defined as the time from date of randomization until death due to any cause.

  3. Duration of response [ Time Frame: Up to approximately 12 months ]
    Defined as the time from the date of the first assessment of CR or PR until the date of the first disease progression by an ICR per RECIST v1.1 or death, whichever occurs first.

  4. Disease control rate [ Time Frame: Up to approximately 12 months ]
    Defined as the proportion of participants who achieved best overall response of CR, PR, or stable disease (SD) per RECIST v1.1 as assessed by an ICR.

  5. Number of treatment-emergent adverse events [ Time Frame: Up to approximately 12 months ]
    Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug.

  6. Quality of Life impact as assessed by the EQ-5D-3L questionnaire [ Time Frame: Up to 12 months ]
  7. Quality of Life impact as assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire [ Time Frame: Up to 12 months ]
  8. Quality of Life impact as assessed by the EORTC QLQ-BIL21 questionnaire [ Time Frame: Up to 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male and female participants at least 18 years of age at the time of signing the informed consent form (ICF); a legally minor participant from Japan needs written parental consent.
  • Histologically or cytologically confirmed cholangiocarcinoma that is previously untreated and considered unresectable and/or metastatic (Stage IV per the American Joint Committee on Cancer (AJCC) Cancer Staging Manual).
  • Radiographically measurable or evaluable disease by CT or MRI per RECIST v1.1 criteria.
  • Eastern Cooperative Oncology Group performance status 0 to 1.
  • Documented FGFR2 rearrangement.
  • Willingness to avoid pregnancy or fathering children.

Exclusion Criteria:

  • Received prior anticancer systemic therapy for unresectable and/or metastatic disease (not including adjuvant/neo-adjuvant treatment completed at least 6 months prior to enrollment, and participants that have received treatment for locally advanced disease with trans-arterial chemoembolization or selective internal radiation therapy, if clear evidence of radiological progression is observed before enrollment).
  • Child-Pugh B and C.
  • Toxicities related to prior therapy(ies) must be Common Terminology Criteria for Adverse Events (CTCAE) v5.0 ≤ Grade 1 at the time of screening.
  • Concurrent anticancer therapy, other than the therapies being tested in this study.
  • Participant is a candidate for potentially curative surgery.
  • Current evidence of clinically significant corneal (including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and keratoconjunctivitis) or retinal disorder (including but not limited to central serous retinopathy, macular/retinal degeneration, diabetic retinopathy, retinal detachment) as confirmed by ophthalmologic examination.
  • Radiation therapy administered within 4 weeks of enrollment/randomization/first dose of study treatment.
  • Known central nervous system (CNS) metastases or history of uncontrolled seizures.
  • Known additional malignancy that is progressing or requires active treatment (exceptions: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy).
  • Laboratory values at screening outside the protocol-defined range.
  • History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues (exception: commonly observed calcifications in soft tissues, such as the skin, kidney, tendons or vessels due to injury, disease, and aging, in the absence of systemic mineral imbalance).
  • Gastrointestinal conditions/disorders that may raise gastric and/or small intestinal pH that could interfere with absorption, metabolism, or excretion of pemigatinib.
  • Clinically significant or uncontrolled cardiac disease.
  • History or presence of an abnormal ECG, which, in the investigator's opinion, is clinically meaningful.
  • Chronic or current active infectious disease requiring systemic antibiotics, antifungal or antiviral treatment within 2 weeks prior to enrollment.
  • Use of any potent CYP3A4 inhibitors or inducers or moderate CYP3A4 inducers within 14 days or 5 half-lives (whichever is longer) before the first dose of study treatment. Note: Moderate CYP3A4 inhibitors are not prohibited
  • Known hypersensitivity or severe reaction to pemigatinib, gemcitabine, cisplatin, or their excipients.
  • Inadequate recovery from toxicity and/or complications from a major surgery before starting therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03656536

Layout table for location contacts
Contact: Incyte Corporation Call Center (US) 1.855.463.3463
Contact: Incyte Corporation Call Center (ex-US) +800 00027423

  Hide Study Locations
Layout table for location information
United States, Arizona
Mayo Clinic Arizona Recruiting
Phoenix, Arizona, United States, 85054
Contact: Study Coordinator    480-342-6029      
United States, California
UC Irvine Medical Center Recruiting
Orange, California, United States, 92868
Contact: Study Coordinator    714-456-6210      
United States, Florida
Mayo Clinic Florida Recruiting
Jacksonville, Florida, United States, 32224
Contact: Study Coordinator    904-953-3814      
Mount Sinai Comprehensive Cancer Center Recruiting
Miami Beach, Florida, United States, 33140
Contact: Study Coordinator    305-674-2625      
United States, Illinois
The University of Chicago Medical Center Recruiting
Chicago, Illinois, United States, 60637
Contact: Study Coordinator    773-702-7763      
United States, Kansas
The University of Kansas Cancer Center Recruiting
Westwood, Kansas, United States, 66205
Contact: Study Coordinator    913-588-1886      
United States, Maryland
The Sidney Kimmel Comprehensive Cancer Center at John Hopkins Recruiting
Baltimore, Maryland, United States, 21287
Contact: Study Coordinator    410-502-5327      
United States, Michigan
Karmanos Cancer Institute Recruiting
Detroit, Michigan, United States, 48201
Contact: Study Coordinator    313-576-8496      
United States, New Jersey
Summit Medical Group PA Recruiting
Florham Park, New Jersey, United States, 07932
Contact: Study Coordinator    973-436-1755      
United States, New York
White Plains Hospital Recruiting
New York, New York, United States, 10601
Contact: Study Coordinator    914-849-7591      
Mayo Clinic Rochester Recruiting
Rochester, New York, United States, 55905
Contact: Study Coordinator    507-284-2030      
United States, Oregon
Oregon Health and Science University Recruiting
Portland, Oregon, United States, 97239
Contact: Study Coordinator    503-494-3175      
United States, Pennsylvania
Fox Chase Cancer Center Recruiting
Philadelphia, Pennsylvania, United States, 19111
Contact: Study Coordinator    215-214-1660      
United States, South Carolina
Greenville Health System Cancer Institute Recruiting
Greenville, South Carolina, United States, 29605
Contact: Study Coordinator    864-699-5731      
United States, Texas
Baylor University - Charles A. Sammons Cancer Center Recruiting
Dallas, Texas, United States, 75246
Contact: Study Coordinator    214-820-6168      
United States, Washington
Virginia Mason Medical Center Recruiting
Seattle, Washington, United States, 98101
Contact: Study Coordinator    206-287-5671      
United States, West Virginia
West Virginia University Hospitals, Inc Recruiting
Morgantown, West Virginia, United States, 26506
Contact: Study Coordinator    304-293-2633      
UZ Leuven Recruiting
Leuven, Belgium, 3000
Contact: Study Coordinator    +3216341940      
Docrates Cancer Center Recruiting
Helsinki, Finland, 00180
Contact: Study Coordinator    +358505001856      
Helsinki University Hospital Recruiting
Helsinki, Finland, 00290
Contact: Study Coordinator    +358505130234      
Azienda Ospedaliero Universitaria Ospedali Ruiniti Recruiting
Ancona, Italy, 60126
Contact: Study Coordinator    +390715965093      
IRCCS Azienda Ospedaliera Universitaria San Martino Recruiting
Genova, Italy, 16132
Contact: Study Coordinator    +390105553977      
Fondazione IRCCS Istituto Nazionale Dei Tumori Recruiting
Milano, Italy, 20133
Contact: Study Coordinator    +390223903835      
Istituto Europeo Di Oncologia Recruiting
Milano, Italy, 20141
Contact: Study Coordinator    +390294372680      
A.O.U Di Modena - Polclinico Recruiting
Modena, Italy, 41124
Contact: Study Coordinator    +393929175678      
Universitaria Degli Studi Della Campania "Luigi Vanvitelli" U.O.C. Oncologia Medica Recruiting
Napoli, Italy, 80138
Contact: Study Coordinator    +390815666688      
Policlinico Universitario Gemelli Recruiting
Rome, Italy, 00168
Contact: Study Coordinator    +393498756270      
Azienda Ospedaliera Universitaria Senese Policlinico Santa Maria Alle Scotte Recruiting
Siena, Italy, 53100
Contact: Study Coordinator    +39577586335      
Azienda Ospedaliera di Verona-Policlinico G.B. Rossi Recruiting
Verona, Italy, 37134
Contact: Study Coordinator    +39458126564      
Saitama Cancer Center Recruiting
Saitama, Kita Adachi-Gun, Japan, 362-0806
Contact: Study Coordinator    +81355755862      
Chiba Cancer Center Recruiting
Chiba, Japan, 260-8717
Contact: Study Coordinator    +81342183500      
National Hospital Organization Kyushu Cancer Center Recruiting
Fukuoka-Shi, Japan, 811-1395
Contact: Study Coordinator    +81925413231      
Hokkaido University Hospital Recruiting
Hokkaido, Japan, 060-8648
Contact: Study Coordinator    +81117067600      
Kobe University Hospital Recruiting
Kobe, Japan, 650-0017
Contact: Study Coordinator    +81783825111      
Cancer Institute Hospital of JFCR Recruiting
Koto-Ku, Japan, 135-8550
Contact: Study Coordinator    +81363164620      
NHO Shikoku Cancer Center Recruiting
Matsuyama, Japan, 791-0280
Contact: Study Coordinator    +81899991196      
Osaka International Cancer Institute Recruiting
Osaka-Shi, Japan, 541-8567
Contact: Study Coordinator    +81662026677      
Keio University Hospital Recruiting
Shinanomachi, Japan, 160-8582
Contact: Study Coordinator    +81353633899      
Toyama University Hospital Recruiting
Toyama, Japan, 930-0194
Contact: Study Coordinator    +81776245900      
Yamaguchi University Hospital Recruiting
Ube, Japan, 755-8505
Contact: Study Coordinator    +81825061631      
Yokohama City University Medical Center Recruiting
Yokohama, Japan, 232-0024
Contact: Study Coordinator    +81452615656      
UMC Utrecht Recruiting
Utrecht, Netherlands, 3584 CX
Contact: Study Coordinator    +31887556263      
Hospital de La Santa Creu I Sant Pau Recruiting
Barcelona, Spain, 08026
Contact: Study Coordinator    +34935565585      
Hospital General Vall d'Hebron Recruiting
Barcelona, Spain, 08035
Contact: Study Coordinator    +34913368263      
Hospital Clinic De Barcelona Recruiting
Barcelona, Spain, 08036
Contact: Study Coordinator    +34932275400 ext 3303      
Hospital Materno Teresa Herrera Recruiting
La Coruña, Spain, 15006
Contact: Study Coordinator    +34981178000 ext 292872      
Hospital General Universitario Gregorio Maranon Recruiting
Madrid, Spain, 28007
Contact: Study Coordinator    +34914269629      
Hospital Universitario Ramon Y Cajal Recruiting
Madrid, Spain, 28034
Contact: Study Coordinator    +34913368263      
Hospital Universitario HM Sanchinarro Recruiting
Madrid, Spain, 28050
Contact: Study Coordinator    +34917567800      
Hospital Universitari Parc Tauli Recruiting
Sabadell, Spain, 08208
Contact: Study Coordinator    +34937240084      
Karolinska University Hospital Recruiting
Stockholm, Sweden, 14141
Contact: Study Coordinator    +46851773484      
United Kingdom
Addenbrooke's Hospital Recruiting
Cambridge, United Kingdom, CB2 0QQ
Contact: Study Coordinator    +441223348076      
The Royal Marsden NHS Foundation Trust Recruiting
London, United Kingdom, SW3 6JJ
Contact: Study Coordinator    +442086426011      
Imperial College Healthcare NHS Trust - Hammersmith Hospital Recruiting
London, United Kingdom, W12 0HS
Contact: Study Coordinator    +442033131000      
The Christie NHS Foundation Trust Recruiting
Manchester, United Kingdom, M20 4BV
Contact: Study Coordinator    +441614468106      
The Royal Marsden NHS Foundation Trust Recruiting
Sutton, United Kingdom, SM2 5PT
Contact: Study Coordinator    +442086426011      
Sponsors and Collaborators
Incyte Corporation
Layout table for investigator information
Study Director: Luis Féliz, MD Incyte Corporation

Layout table for additonal information
Responsible Party: Incyte Corporation Identifier: NCT03656536     History of Changes
Other Study ID Numbers: INCB 54828-302
First Posted: September 3, 2018    Key Record Dates
Last Update Posted: August 9, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Incyte Corporation:
fibroblast growth factor receptor inhibitor
FGFR rearrangement
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs